We are live on ! Find out more
MC

Marcus Capital Portfolio holdings

AUM $34.3M
1-Year Est. Return 30.44%
This Fund
S&P 500
This Quarter Est. Return
-6.03%
1 Year Est. Return
+30.44%
3 Year Est. Return
+101.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$90.8M
AUM Growth
-$3.32M
Cap. Flow
+$4.99M
Cap. Flow %
5.49%
Top 10 Hldgs %
37.76%
Holding
54
New
5
Increased
19
Reduced
13
Closed
3

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$2.64M
2
TWTR
Twitter, Inc.
TWTR
+$1.32M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$1.21M
4
RLYP
RELYPSA INC COM
RLYP
+$1.12M
5
HAR
Harman International Industries
HAR
+$810K

Top Sells

Rank Stock Value
1
XLNX
Xilinx Inc
XLNX
+$2.35M
2
WDAY icon
Workday
WDAY
+$665K
3
ANET icon
Arista Networks
ANET
+$636K
4
AMZN icon
Amazon
AMZN
+$596K
5
CMG icon
Chipotle Mexican Grill
CMG
+$464K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 22.61%
2 Technology 19.44%
3 Financials 12.87%
4 Healthcare 11.43%
5 Consumer Staples 9.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
51
Pfizer
PFE
$143B
$202K 0.22%
7,167
– –
META icon
52
Meta Platforms (Facebook)
META
$1.54T
– –
-3,000
Closed -$314K
XLNX
53
DELISTED
Xilinx Inc
XLNX
– –
-50,000
Closed -$2.35M
PVCT
54
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
– –
-15,000
Closed -$6K
1 2
3

Similar funds

PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
RIA
Rocaton Investment Advisors Norwalk, Connecticut $36.6M AUM 10.31% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
IP
Ironsides Partners Boston, Massachusetts $27.7M AUM 1.11% 1-Year Est. Return
DCM
Dearborn Capital Management Chicago, Illinois $41.6M AUM 2.79% 1-Year Est. Return
PA
Pastel & Associes Paris, France $43.8M AUM 18.14% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return

Marcus Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Marcus Capital held 54 positions worth $90.8M, down 3.5% from $94.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Marcus Capital deployed $4.99M of net new capital in Q1 2016, opening 5 new positions and adding to 19 existing holdings. Its largest new stake was Biogen: 10,000 shares worth $2.6M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 23% of assets, down from 24% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Workday, an estimated $665K trimmed.

  • Marcus Capital's largest Q1 2016 buy was Biogen: 10,000 shares worth $2.6M.
  • Marcus Capital added most to Twitter, Inc. in Q1 2016, an estimated $1.32M increase.
  • Marcus Capital's biggest Q1 2016 reduction was Workday, cutting an estimated $665K.
  • Marcus Capital fully exited Xilinx Inc in Q1 2016, selling an estimated $2.35M.
  • Marcus Capital's ten largest holdings make up 38% of its $90.8M portfolio in Q1 2016.
  • Marcus Capital opened 5 new positions and closed 3 in Q1 2016.
  • Marcus Capital's portfolio value fell 3.5% quarter-over-quarter to $90.8M.

Based on Marcus Capital's 13F filing for Q1 2016, filed 10 May 2016.